Growth hormone alleviates oxidative stress and improves the IVF outcomes of poor ovarian responders: a randomized controlled trial.

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this randomized controlled trial publication.

Registered 8 February 2019, http://www.chictr.org.cn/edit.aspx?pid=35837&htm=4.

Who Took Part

The abstract describes 105 patients taking part.

PubMed indexes the participants as adults, women only.

This study enrolled 105 patients with POR and 58 patients without POR (controls) who were diagnosed according to the Bologna criteria and underwent conventional IVF-ET.

How the Study Was Run

The design is described as randomized.

The patients were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.

OS markers in follicular fluid (FF), ROS levels in granulosa cells (GCs), and the IVF outcomes of the groups were compared.

What Was Measured

The subject headings attached to it are China, Fertilization in Vitro, Human Growth Hormone, Infertility, Female, Ovarian Reserve, Ovary and Ovulation Induction.

The authors tagged it with the keywords In vitro fertilization, Oxidative stress, Poor ovarian response and Reactive oxygen species.

What This Means in Plain Language

The paper is a randomized study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 105 patients.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2020 (Reproductive biology and endocrinology : RB&E), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.